Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation

Bone Marrow Transplantation

Volumn 20, Issue 7, 1997, Pages 533-541

  Glass, B ^a,c   Majolino, I ^b   Dreger, P ^a   Scime R ^b   Santoro, A ^b   Vasta, S ^b   Suttorp, M ^a   Haferlach, T ^a   Schmitz, N ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Donor leukocyte infusion; Graft versus leukemia effect; Hematopoietic stem cell transplantation; Peripheral progenitor cells; Relapse

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PANCYTOPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030707878     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700934     Document Type: Article

References (46)

1. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
2. Spinolo JA, Yau JC, Dicke KA et al. Second bone marrow transplants for relapsed leukemia. Cancer 1992; 69: 405-409.
3. Sica S, Salutari P, Di Mario A et al. Aggressive chemotherapy for acute leukemia relapsed after transplantation. Leuk Lymphoma 1994; 15: 131-134.
4. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211-3219.
5. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
6. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for replased chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
7. Bär BM, Schattenberg A, Mensink EJ et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
8. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
9. Jiang YZ, Cullis JO, Kanfer EJ et al. T cell and NK cell mediated graft-veresus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993; 11: 133-138.
10. Hertenstein B, Wiesneth M, Novotny J et al. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic hone marrow trans-plantation. Transplantation 1993; 56: 1114-1118.
11. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
12. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
13. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
14. Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thyldim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
15. Buscemi F, Fabbiano F, Felice R et al. Use of large polygonal contiguous gates for flow cytometry analysis of circulating progenitor cells (letter). Bone Marrow Transplant 1993; 12: 305-306.
16. Suttorp M, Schmitz N, Dreger P et al. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. Leukemia 1993; 7: 679-687.
17. Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism following T-cell-depleted bone marrow transplantation (BMT): evaluation of conditioning regimens using the polymerase chain reaction (PCR) to amplify human minisatellite regions of genomic DNA (meeting abstract). Exp Hematol 1992; 20: 721.
18. Majolino I, Saglio G, Schime R. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-560.
19. Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
20. Weber-Matthiesen K, Winkemann M, Muller-Hermelink A, Schlegelberger BGW. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem 1992; 40: 171-175.
21. Haferlach T, Winkemann M, Löffler H et al. The abnormal eosinophils are part of the leukemic cell population in AML M4Eo and carry the pericentric inversion 16: a combination of May-Grünwald staining and fluorescence in situ hybridization. Blood 1996; 87: 2459-2463.
22. Schoch R, Jenisch S, Haferlach T et al. Glass slide smears are a suitable source for RT-PCR-based analysis of chromosomal aberrations in leukaemias. Br J Haematol 1996; 92: 140-142.
23. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorofom extraction. Anal Biochem 1987; 162: 156-159.
24. Maurer J, Janssen JWG, Thiel E et al. Detection of BCR/ABL genes in acute lymphoblastic leukemia by polymerase chair reaction. Lancet 1991; 337: 1055-1058.
25. Hughes TP, Goldman JM. Improved results with PCR for chronic myeloid leukemia. Lancet 1990; 336: 812.
26. Biondi A, Rambaldi A, Pandolfi PP et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
27. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
28. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by G-CSF (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
29. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
30. Sosman JA, Oettel KR, Hank JA et al. Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation 1989; 48: 486-495.
31. Sosman JA, Oettel KR, Smith SD et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75: 2005-2016.
32. Glass B, Uharek L, Zeis M et al. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996; 93: 412-420.
33. Zeis M, Uharek L, Glass B et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995; 59: 1734-1736.
34. Giralt S, Champlin RE. Leukemia relapse after bone marrow transplantation: a review. Blood 1994; 84: 3603-3612.
35. Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50-57.
36. Bostrom B, Woods WG, Nesbit ME et al. Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation. J Clin Oncol 1987; 5: 376-381.
37. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995; 23: 196-201.
38. Drobyski WR, Baxter-Lowe LA, Truitt RL. Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease. Blood 1993; 81: 551-559.
39. Slavin S, Or R, Kapelushnik Y et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 1992; 6 (Suppl. 4): 164-166.
40. Flowers ME, Sullivan KM, Martin P et al. G-CSF stimulated donor peripheral blood infusions as immunotherapy in patients with hematologic malignancies relapsing after allogeneic transplantation. Blood 1995; 86: 564a.
41. Tringali S, Vasta S, Scime R, Majolino I. Testicular relapse of AML during chronic GVHD induced by donor leukocyte infusion. Haematologica 1996; 81: 339-342.
42. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
43. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
44. Pan L, Delmonte J, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
45. Krenger W, Snyder KM, Byon JCH et al. Polarized type 2 alloreactive CD4+ and CD8+ donor cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585-593.
46. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.